Sylentis
Spain - Madrid
BiotechnologyFocus: RNAi Treatments
Sylentis is a life sciences company focused on RNAi Treatments.
Gene Therapy
Open Jobs
0
Pipeline & Clinical Trials
SYL1001
Ocular PainClinical Trials (1)
NCT01438281Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers
Phase 1SYL040012
Ocular HypertensionClinical Trials (1)
NCT00990743Tolerance and Effect on Intraocular Pressure After Administration of SYL040012
Phase 1SYL18001 sodium Low dose q.d
Safety, Tolerability and Pharmacokinetic Profile in Healthy VolunteersClinical Trials (1)
NCT04782271Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops
Phase 1SYL040012
GlaucomaClinical Trials (1)
NCT01227291SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With Intraocular Pressure (IOP) >= 21 mm Hg
Phase 1/2SYL1001
Ocular PainClinical Trials (1)
NCT01776658Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain
Phase 1/2SYL040012
Ocular HypertensionClinical Trials (1)
NCT01739244Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle Glaucoma
Phase 21 drop of 0.375% SYL040012
Open Angle GlaucomaClinical Trials (1)
NCT02250612SYL040012, Treatment for Open Angle Glaucoma
Phase 2SYL1001
Ocular PainClinical Trials (1)
NCT02455999Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain
Phase 2SYL1801
Wet Macular DegenerationClinical Trials (1)
NCT05637255A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)
Phase 2Tivanisiran sodium ophthalmic solution
Dry Eye DiseaseClinical Trials (1)
NCT04819269Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
Phase 3Tivanisiran sodium ophthalmic solution
Dry Eye DiseaseClinical Trials (1)
NCT05310422Safety Study of Tivanisiran to Treat Dry Eye
Phase 3SYL1001 ophthalmic solution
Dry Eye DiseaseClinical Trials (1)
NCT03108664HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 12 clinical trials